Enlivex Ltd. (ENLV)
ENLV trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | ENLV on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Israel |
| IPO year | 2014 |
| SEC CIK | 0001596812 |
| SEC industry code | Finance Services |
| Incorporated in | Israel |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-03-25 |
| Cash and burn | $1.9M cash; operating cash flow -$2.6M a quarter. | Report 2025-12-31 |
| Shares outstanding | 989,090 (2025-12-31); 23,650,989 a year earlier; 18,421,852 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | 2; latest 1-for-16 on 2026-10-27 | Source 2026-10-27 |
| Shelf and offerings, 12 months | 3 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2025-11-24 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Yarel + Partners, Tel Aviv-Yafo, Israel | PCAOB Form AP 2026-04-02 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
| Market cap check | The listing's market cap implies 1,531,995 shares at the 2026-11-13 price; the latest SEC cover count is 989,090 as of 2025-12-31, 989,090 after the 1-for-15 and 1-for-16 splits since. The SEC count is the older of the two, so the listing's cap is likely the current one; shares were issued since that cover page. | Nasdaq screener and SEC cover page |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | Not filed | $1.2B | -$10.4M | $1.9M | No debt tags | Needs four quarters | 20-F 2026-03-25 |
| FY 2024 2024-12-31 | Not filed | -$15.0M | -$13.0M | $3.3M | No debt tags | Needs four quarters | 20-F 2026-03-25 |
| FY 2023 2023-12-31 | Not filed | -$29.1M | -$23.5M | $813K | No debt tags | Needs four quarters | 20-F 2026-03-25 |
| FY 2022 2022-12-31 | Not filed | -$31.1M | -$24.0M | $49.9M | No debt tags | Needs four quarters | 20-F 2025-04-30 |
| FY 2021 2021-12-31 | Not filed | -$14.5M | -$17.5M | $11.2M | No debt tags | Needs four quarters | 20-F 2024-04-30 |
| FY 2020 2020-12-31 | Not filed | -$11.8M | -$11.0M | $5.7M | No debt tags | Needs four quarters | 20-F 2023-04-10 |
| FY 2019 2019-12-31 | Not filed | -$9.4M | -$7.0M | $3.9M | No debt tags | Needs four quarters | 20-F 2022-04-29 |
| FY 2018 2018-12-31 | Not filed | -$4.2M | -$3.2M | $9.7M | No debt tags | Needs four quarters | 20-F 2021-04-30 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B3 | 2026-08-17 |
| Latest annual report ANNUAL REPORT | 20-F | 2026-03-25 |
| Latest quarterly / interim REPORT OF FOREIGN PRIVATE ISSUER | 6-K | 2026-11-16 |
Source: SEC EDGAR submissions feed, 420 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -6.3% |
| 1 month | +436.0% |
| 3 months | -29.6% |
| Year to date | -88.7% |
| 1 year | -92.0% |
| From 52-week high | -93.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SXTP | 60 Degrees Pharmaceuticals Inc. | $0.4938 | -4.65% | $1.7M |
| HCWB | HCW Biologics Inc. | $0.8000 | +3.48% | $1.8M |
| ARTL | Artelo Biosciences Inc. | $1.70 | -17.87% | $1.6M |
| XRTX | XORTX Therapeutics Inc. Common Shares | $1.04 | -5.45% | $1.9M |
| ONCO | Onconetix Inc. | $2.91 | -9.35% | $1.9M |
| PPCB | Propanc Biopharma Inc. | $1.89 | -2.62% | $2.0M |
| APVO | Aptevo Therapeutics Inc. | $0.5486 | -7.66% | $1.5M |
| CMND | Clearmind Medicine Inc. Common Shares | $4.18 | -7.67% | $2.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier